Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize Galafold as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone609-662-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$91.25 million
Profitability
Miscellaneous
Employees508
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions
What is Amicus Therapeutics' stock symbol?
Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."
How were Amicus Therapeutics' earnings last quarter?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings data on Thursday, February, 28th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.13. The biopharmaceutical company earned $32.64 million during the quarter, compared to the consensus estimate of $30.81 million. Amicus Therapeutics had a negative return on equity of 54.21% and a negative net margin of 382.48%. The firm's revenue for the quarter was up 121.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.41) earnings per share. View Amicus Therapeutics' Earnings History.
When is Amicus Therapeutics' next earnings date?
What guidance has Amicus Therapeutics issued on next quarter's earnings?
Amicus Therapeutics updated its FY 2019 earnings guidance on Thursday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $160-180 million, compared to the consensus revenue estimate of $175.81 million.
What price target have analysts set for FOLD?
5 equities research analysts have issued 12-month price targets for Amicus Therapeutics' shares. Their predictions range from $12.59 to $31.00. On average, they anticipate Amicus Therapeutics' stock price to reach $19.3180 in the next year. This suggests a possible upside of 45.7% from the stock's current price. View Analyst Price Targets for Amicus Therapeutics.
What is the consensus analysts' recommendation for Amicus Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amicus Therapeutics.
What are Wall Street analysts saying about Amicus Therapeutics stock?
Here are some recent quotes from research analysts about Amicus Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "We rate Amicus Therapeutics Overweight. Amicus focuses on treatments for lysosomal storage disorders and rare diseases. We foresee Galafold as becoming the standard of care for Fabry disease patients with amenable mutations around the world. We think beyond this approval, Amicus has a robust pipeline." (2/26/2019)
- 2. According to Zacks Investment Research, "2018 was great for Amicus as it received U.S. approval forits only marketed drug Galafold, expanded its pipeline to include 14 new gene therapy programs for rare metabolic diseases and also presented a positive 18-month data for its differentiated Pompe pipeline product. Amicus estimates peak sales opportunity for Galafold to be more than $500 million. The company also expects to almost double the revenues for Galafold in 2019. However, it depends heavily on Galafold sales, which remains a concern. Shares of the company have underperformed the industry in the past year. Loss estimates have remained stable ahead of the Q4 earnings release and the company came up with average negative surprise for the trailing four reported quarters." (2/4/2019)
Has Amicus Therapeutics been receiving favorable news coverage?
News stories about FOLD stock have trended neutral this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amicus Therapeutics earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the immediate future.
Are investors shorting Amicus Therapeutics?
Amicus Therapeutics saw a decline in short interest during the month of February. As of February 15th, there was short interest totalling 19,050,813 shares, a decline of 13.7% from the January 31st total of 22,063,910 shares. Based on an average daily volume of 2,885,749 shares, the days-to-cover ratio is currently 6.6 days. Approximately 10.4% of the shares of the stock are short sold. View Amicus Therapeutics' Current Options Chain.
Who are some of Amicus Therapeutics' key competitors?
Some companies that are related to Amicus Therapeutics include Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Loxo Oncology (LOXO), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Catalent (CTLT), Marina Biotech (MRNA), Nektar Therapeutics (NKTR) and Amarin (AMRN).
What other stocks do shareholders of Amicus Therapeutics own?
Who are Amicus Therapeutics' key executives?
Amicus Therapeutics' management team includes the folowing people:
- Mr. John F. Crowley, Chairman & CEO (Age 52)
- Mr. Bradley L. Campbell, Pres, COO & Director (Age 43)
- Ms. Ellen S. Rosenberg, Chief Legal Officer & Corp. Sec. (Age 56)
- Dr. Jay A. Barth, Chief Medical Officer (Age 55)
- Ms. Daphne E. Quimi, Chief Financial Officer (Age 53)
Who are Amicus Therapeutics' major shareholders?
Amicus Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (10.95%), FMR LLC (9.48%), BlackRock Inc. (8.73%), venBio Select Advisor LLC (5.35%), Jennison Associates LLC (5.19%) and Sectoral Asset Management Inc (2.66%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.
Which institutional investors are selling Amicus Therapeutics stock?
FOLD stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Orbimed Advisors LLC, Victory Capital Management Inc., Bank of America Corp DE, American Century Companies Inc., Asymmetry Capital Management L.P., Jennison Associates LLC and Principal Financial Group Inc.. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Margaret G Mcglynn, Michael Raab and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics.
Which institutional investors are buying Amicus Therapeutics stock?
FOLD stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Norges Bank, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, venBio Select Advisor LLC, Assenagon Asset Management S.A., Sphera Funds Management LTD. and Delek Group Ltd.. Company insiders that have bought Amicus Therapeutics stock in the last two years include John F Crowley, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.
How do I buy shares of Amicus Therapeutics?
Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amicus Therapeutics' stock price today?
One share of FOLD stock can currently be purchased for approximately $13.26.
How big of a company is Amicus Therapeutics?
Amicus Therapeutics has a market capitalization of $2.97 billion and generates $91.25 million in revenue each year. The biopharmaceutical company earns $-348,990,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Amicus Therapeutics employs 508 workers across the globe.
What is Amicus Therapeutics' official website?
How can I contact Amicus Therapeutics?
Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]
MarketBeat Community Rating for Amicus Therapeutics (NASDAQ FOLD)
MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe FOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
